DARE BIOSCIENCE INC. - COMMON STOCK

Daré Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO™ (Clindamycin Phosphate) Vaginal Gel, 2%, FDA-Approved Treatment for Bacterial Vaginosis in Females 12 Years or Older

16 Oct 2023 07:00:01 By Nasdaq GlobeNewswire

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

21 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Daré Bioscience to Present at The Menopause Society 2023 Annual Meeting

20 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Daré Bioscience to Participate in Upcoming Investor Conferences

06 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Completes Previously Announced Equity Financing

05 Sep 2023 07:00:01 By Nasdaq GlobeNewswire

Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

30 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update

10 Aug 2023 07:00:02 By Nasdaq GlobeNewswire

Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of DARE-HRT1 Intravaginal Rings

09 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023

03 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

Daré Bioscience Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth

31 Jul 2023 07:00:01 By Nasdaq GlobeNewswire

Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems

11 Jul 2023 16:30:00 By Nasdaq GlobeNewswire

Daré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women

11 Jul 2023 07:00:01 By Nasdaq GlobeNewswire

Daré Bioscience Announces Upcoming Webinar to Review Additional Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

06 Jul 2023 07:00:01 By Nasdaq GlobeNewswire

Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis

05 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1/2 Open-Label Safety and Pharmacokinetics Study of DARE-HRT1 in Healthy Postmenopausal Women

21 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Daré Bioscience to Present at the Maxim Group Virtual Healthcare Conference

14 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Announces Publication of Phase 1/2 Pharmacokinetic, Safety and Pharmacodynamic Data for DARE-VVA1 - a Potential New Hormone-Free Treatment for Vulvovaginal Atrophy - in Climacteric, the Journal of the International Menopause Society

09 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Announces Positive Topline Data from the Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

05 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Daré Bioscience to Participate in Two Upcoming Conferences: 2023 BIO International Convention and the Longwood Healthcare Leaders Spring 2023 MIT Conference

01 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Daré Bioscience Announces Availability of Publication on the Patient-Centered Concept Elicitation Study for Female Sexual Arousal Disorder in The Journal of Sexual Medicine

31 May 2023 07:00:01 By Nasdaq GlobeNewswire